Welcome to LookChem.com Sign In|Join Free

CAS

  • or
DIETHYL (BOC-AMINO)MALONATE, with the chemical name Diethyl (Boc-amino)malonate and CAS number 102831-44-7, is a colorless oil compound that plays a significant role in organic synthesis. Its unique chemical properties make it a valuable component in various chemical reactions and processes.

102831-44-7

Post Buying Request

102831-44-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

102831-44-7 Usage

Uses

Used in Organic Synthesis:
DIETHYL (BOC-AMINO)MALONATE is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its versatility and reactivity in chemical reactions make it an essential component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, DIETHYL (BOC-AMINO)MALONATE is used as a building block for the synthesis of various drug molecules. Its ability to form stable intermediates and participate in multiple reaction pathways allows for the development of new and innovative medications.
Used in Agrochemical Industry:
DIETHYL (BOC-AMINO)MALONATE is also utilized in the agrochemical industry for the synthesis of active ingredients in pesticides and herbicides. Its role in creating stable and effective compounds contributes to the development of more efficient and environmentally friendly agricultural products.
Used in Specialty Chemicals:
In the specialty chemicals sector, DIETHYL (BOC-AMINO)MALONATE is employed as a precursor for the synthesis of various high-value compounds. Its unique chemical properties enable the production of specialty chemicals used in industries such as coatings, adhesives, and plastics.

Check Digit Verification of cas no

The CAS Registry Mumber 102831-44-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,2,8,3 and 1 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 102831-44:
(8*1)+(7*0)+(6*2)+(5*8)+(4*3)+(3*1)+(2*4)+(1*4)=87
87 % 10 = 7
So 102831-44-7 is a valid CAS Registry Number.
InChI:InChI=1/C12H21NO6/c1-6-17-9(14)8(10(15)18-7-2)13-11(16)19-12(3,4)5/h8H,6-7H2,1-5H3,(H,13,16)

102831-44-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (448486)  Diethyl(Boc-amino)malonate  97%

  • 102831-44-7

  • 448486-25ML

  • 2,451.15CNY

  • Detail

102831-44-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Diethyl (Boc-amino)malonate

1.2 Other means of identification

Product number -
Other names Diethyl 2-(tert-Butoxycarbonylamino)malonate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:102831-44-7 SDS

102831-44-7Relevant articles and documents

Studies toward the synthesis of caramboxin analogues

Oliveira Filho, Ronaldo E.,Higa, Vanessa M.,Omori, álvaro T.

, p. 528 - 540 (2019)

Intrigued by the recent discovery of caramboxin by Brazilian researchers, we present the results from our studies toward the racemic synthesis of caramboxin analogs through the ortho-carboxylation of 3,5-dimethoxy benzyl derivatives. Three different approaches were tested, and the route involving a Vilsmeier-Haack formylation followed by a Lindgren oxidation provide a potential intermediate for the synthesis of several caramboxin analogs.

Glutathione peroxidase-like activity of amino-substitutedwater-soluble cyclic selenides: A shift of the major catalytic cycle in methanol

Arai, Kenta,Tashiro, Ayako,Osaka, Yuui,Iwaoka, Michio

, (2017)

We previously reported that water-soluble cyclic selenides can mimic the antioxidative function of glutathione peroxidase (GPx) in water through a simple catalytic cycle, in which the selenide (>Se) is oxidized by H2O2 to the selenoxide (>Se=O) and the selenoxide is reduced by a thiol back to the selenide. In methanol, however, the GPx-like activity could not be explained by this simple scenario. To look into the reasons for the unusual behaviors in methanol, monoamino-substituted cyclic selenides with a variable ring size were synthesized, and the intermediates of the catalytic cycle were characterized by means of 77Se-NMR and LC-MS spectroscopies. In water, it was confirmed that the selenide and the selenoxide mainly contribute to the antioxidative function, though a slight contribution from the dihydroxy selenane (>Se(OH)2) was also suggested. In methanol, on the other hand, other active species, such as hydroxyselenonium (>Se+-OH) and hydroxy perhydroxy selenane (>Se(OH)(OOH)), could be generated to build another catalytic cycle. This over-oxidation would be more feasible for amino-substituted cyclic selenides, probably because the ammonium (NH3 +) group would transfer a proton to the selenoxide moiety to produce a hydroxyselenonium species in the absence of an additional proton source. Thus, a shift of the major catalytic cycle in methanol would make the GPx-like antioxidative function of selenides perplexing.

Access to Enantiopure α-Hydrazino Acids for N-Amino Peptide Synthesis

Kang, Chang Won,Sarnowski, Matthew P.,Elbatrawi, Yassin M.,Del Valle, Juan R.

, p. 1833 - 1841 (2017)

Backbone N-methylation of α-peptides has been widely employed to enhance the bioavailability and bioactivity of parent sequences. Heteroatomic peptide amide substituents have received less attention due, in part, to the lack of practical synthetic strategies. Here, we report the synthesis of α-hydrazino acids derived from 19 out of the 20 canonical proteinogenic amino acids and demonstrate their use in the solid-phase synthesis of N-amino peptide derivatives.

Biotinidase Resistant 68Gallium-Radioligand Based on Biotin/Avidin Interaction for Pretargeting: Synthesis and Preclinical Evaluation

Prakash, Surbhi,Hazari, Puja Panwar,Meena, Virendra Kumar,Jaswal, Ambika,Khurana, Harleen,Kukreti, Shrikant,Mishra, Anil Kumar

, p. 2780 - 2790 (2016)

A new macrocyclic system 2,2′-(12-amino-11,13-dioxo-1,4,7,10-tetraazacyclotridecane-4,7-diyl)diacetic acid (ATRIDAT) was designed for coordinating metals in +2 and +3 oxidation states particularly 68Ga(III), for PET imaging. ATRIDAT was conjugated to d-biotin for pretargeting via biotin-avidin interaction. This model provides high tumor targeting efficiency and stability to biotinidase activity leading to modest signal amplification at the tumor site. Cyclization of triethylenetetramine with protected diethylamino malonate resulted in the formation of 13 membered diamide ring. d-Biotin was then anchored on the pendant amine rendering α-methyne carbon to the biotinamide bond which blocks the biotinidase enzyme activity. Biotinidase stability assay showed remarkable stability toward the action of biotinidase with ~95% remaining intact after treatment following 4 h. Binding affinity experiments such as HABA assay, competitive displacement studies with d-biotin and CD showed high binding affinity of the molecule with avidin in nanomolar range. Biotin conjugate was successfully radiolabeled with 68Ga(III) with radiolabeling efficiency of ~70% and then purified to get 99.9% radiochemical yield. IC50 of the compound was found to be 2.36 mM in HEK cell line and 0.82 mM in A549 as assessed in MTT assay. In biodistribution studies, the major route of excretion was found to be renal. Significant uptake of 4.15 ± 0.35% was observed in tumor in the avidin pretreated mouse at 1 h. μPET images also showed a high tumor to muscle ratio of 26.8 and tumor to kidney ratio of 1.74 at 1 h post-injection after avidin treatment.

β-Methyleneglutamic Acid and β-Methyleneglutamine

Paik, Yi Hyon,Dowd, Paul

, p. 2910 - 2913 (1986)

The novel β,γ-unsaturated amino acids β-methyleneglutamic acid (I) and β-methyleneglutamine (II) are readily prepared by addition of the protected aminomalonates III and VIII to the allenes ethyl buta-2,3-dienoate (IV) and cyanoallene (VII) followed by acid hydrolysis.Byproducts of the reaction are 4-amino-3-methylbut-2-enoic acid hydrochloride (VI) and 4-amino-3-methylbut-2-enamide hydrochloride (X).

Demonstrating Ligandability of the LC3A and LC3B Adapter Interface

Hartmann, Markus,Huber, Jessica,Kramer, Jan S.,Heering, Jan,Pietsch, Larissa,Stark, Holger,Odadzic, Dalibor,Bischoff, Iris,Fürst, Robert,Schr?der, Martin,Akutsu, Masato,Chaikuad, Apirat,D?tsch, Volker,Knapp, Stefan,Biondi, Ricardo M.,Rogov, Vladimir V.,Proschak, Ewgenij

, p. 3720 - 3746 (2021/05/04)

Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to their selective fusion with lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure-activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein interaction targets and will lay the foundation for the development of more potent chemical probes for the Atg8 protein family which may also find applications for the development of autophagy-mediated degraders (AUTACs).

Amine-Directed Palladium-Catalyzed C?H Halogenation of Phenylalanine Derivatives

Ville, Alexia,Annibaletto, Julien,Coufourier, Sébastien,Hoarau, Christophe,Tamion, Rodolphe,Journot, Guillaume,Schneider, Cédric,Brière, Jean-Fran?ois

supporting information, p. 13961 - 13965 (2021/09/14)

An efficient primary-amine-directed, palladium-catalyzed C?H halogenation (X=I, Br, Cl) of phenylalanine derivatives is reported on a range of quaternary amino acid (AA) derivatives thanks to suitable conditions employing trifluoroacetic acid as additive. The extension of this original native functionality-directed ortho-selective halogenation was even demonstrated with the more challenging native phenylalanine as tertiary AA.

COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE

-

Page/Page column 147, (2020/01/24)

The present invention provides compounds of formula (I) for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

Polybasic nitrogen heterocyclic non-natural chiral amino acid and synthesis method thereof

-

Paragraph 0063; 0065; 0066; 0093; 0095; 0096; 0123-0126, (2018/11/22)

The invention relates to a polybasic nitrogen heterocyclic non-natural chiral amino acid and a synthesis method thereof. The amino acid can be applied to molecule building for antibiotic synthesis. According to the synthesis method, 2-aminodiethyl malonate and halogenated alkanes carry out substitution reactions, cyclization reactions, and decarboxylation reactions, and the reaction products are split to obtain the polybasic nitrogen heterocyclic non-natural chiral amino acid. The provided novel synthesis method has the advantages of simple synthesis route, low cost, convenient operation, andeasiness for commercial production, the chiral purity of obtained products is high, and the application prospect is good.

PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS

-

Paragraph 0399; 0400, (2018/07/15)

The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 102831-44-7